TrialCancer chemotherapy and pharmacology2017

A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo.

Makoto Ueno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.